Evidence map›Paper›PMID 28503325›Full record

ArticleSpinal cord series and cases2017

Ceftolozane/tazobactam for febrile UTI due to multidrug-resistant

Aurélien Dinh, Benjamin Davido, Ruxandra Calin, Julie Paquereau, Clara Duran, Frédérique Bouchand, Véronique Phé, Emmanuel Chartier-Kastler, Martin Rottman, Jérôme Salomon and 2 more

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Spinal cord series and cases, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed, 1 pooled it
0.7field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 synthesis or guideline pooled it, 6 citations in OpenAlex.

  1. Real-world use of ceftolozane/tazobactam: a systematic literature review.Antimicrobial resistance and infection control · 2021
    Pooled it
  2. Antibiotic prophylaxis prior to urodynamic study in patients with traumatic spinal cord injury. Is there an indication?International braz j urol : official journal of the Brazilian Society of Urology
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 5 institutions in 1 country.

Aurélien DinhInfectious Disease Unit, Raymond Poincaré University Hospital, AP-HP, Versailles Saint Quentin University, Garches, France.
Benjamin DavidoInfectious Disease Unit, Raymond Poincaré University Hospital, AP-HP, Versailles Saint Quentin University, Garches, France.
Ruxandra CalinInfectious Disease Unit, Raymond Poincaré University Hospital, AP-HP, Versailles Saint Quentin University, Garches, France.
Julie PaquereauPhysical Medicine And Rehabilitation Department, Raymond Poincaré University Hospital, AP-HP, Versailles Saint Quentin University, Garches, France.
Clara DuranInfectious Disease Unit, Raymond Poincaré University Hospital, AP-HP, Versailles Saint Quentin University, Garches, France.
Frédérique BouchandPharmacy Department, Raymond Poincaré University Hospital, AP-HP, Versailles Saint Quentin University, Garches, France.
Véronique PhéUrology Department, Pitié Salpêtrière University Hospital, AP-HP, Paris, France.
Emmanuel Chartier-KastlerUrology Department, Pitié Salpêtrière University Hospital, AP-HP, Paris, France.
Martin RottmanMicrobiology Laboratory, Raymond Poincaré University Hospital, AP-HP, Versailles Saint Quentin University, Garches, France.
Jérôme SalomonInfectious Disease Unit, Raymond Poincaré University Hospital, AP-HP, Versailles Saint Quentin University, Garches, France.
Patrick PlésiatFrench National Reference Centre for Antibiotic Resistance, University Hospital of Besançon, Besançon, France.
Anaïs PotronFrench National Reference Centre for Antibiotic Resistance, University Hospital of Besançon, Besançon, France.
Université de Versailles Saint-Quentin-en-Yvelines · FRCentre Hospitalier Universitaire de Besançon · FRSorbonne Université · FRAssistance Publique – Hôpitaux de Paris · FRInserm · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionUrinary tract infections (UTI) are a major public health problem among spinal cord injury (SCI) patients. They frequently involve multidrug-resistant (MDR) bacteria. Ceftolozane/tazobactam (C/T) is a novel antibiotic combination approved for complicated intra-abdominal and UTI caused by Gram-positive and Gram-negative organisms, including some MDR strains. Little is known about the use of this agent for complicated febrile UTI occurring among SCI patients with neurogenic bladder due to MDR CASE PRESENTATION: We describe the case of a 35-year-old man with SCI due to multiple sclerosis, with a neurogenic bladder necessitating a bilateral nephrostomy and double J catheter, who developed a febrile UTI due to a MDR PSA, which was susceptible only to amikacin and colistin. Because of this MDR phenotype and the underlying kidney disease, a 1000 mg (1000 mg per 500 mg) dose of C/T was given as monotherapy every 8 h for 7 days, after 3 days of colistin and amikacin. Thanks to this treatment, the patient had a favorable outcome with no clinical signs of UTI or positive urine culture up to 1 month after diagnosis. DISCUSSION: C/T seems to be an effective and safe therapeutic option for febrile UTI due to MDR PSA in SCI patients with neurogenic bladder, even when administered in monotherapy for 10 days.

Indexed as

Bacterial infectionInfectious diseases

Identifiers

PMID28503325
PMCPMC5425957
OpenAlexW2612504852

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.